Resources Repository
-
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Technology Assessment | Value of Information | Health/Medicine | North America | Preferences/Values | Priority Setting/Ethics | Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Mental Health | Health Systems | Business/Industry | Economics/Finance | Government/Law | Science/Technology | Europe -
Resource PortalWeb Portal, Teaching Resource 2024National Academies of Sciences, Engineering, and Medicine
The National Academies of Sciences, Engineering, and Medicine, founded in 1863, has a mission to provide …
The National Academies of Sciences, Engineering, and Medicine, founded in 1863, has a mission to provide nonpartisan, objective guidance for decision makers on policy challenges in the context of science, engineering, and medicine. NAS reports and convening activities have a wide range of impacts on policy and practice. They guide the development of federal laws and regulations, improve the effectiveness of government programs, shape the direction of research fields, and inform public knowledge and dialogue about…
Technology Assessment | Health/Medicine | Climate/Environment | North America | Priority Setting/Ethics | Health Outcomes | Evidence Synthesis | Risk Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Injuries/Accidents | Social Determinants | Health Systems | Global Governance | Energy/Engineering | Education/Labor | Food/Agriculture | Military/Defense | Science/Technology | Global | High School | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
BookPublication 2015Methods for the Economic Evaluation of Health Care Programmes, 4th Edition
The 2015 edition of Methods for the Economic Evaluation of Health Care Programmes provides a …
The 2015 edition of Methods for the Economic Evaluation of Health Care Programmes provides a 'tool kit' for undertaking health economic evaluations. The report is aimed at researchers, health service professionals and policy makers without a formal economics background. The recommendations are based on the authors' own experiences and so are practical in nature. The book describes the challenges of allocating resources efficiently and fairly, including challenges in methodology and policy formation. Examples are provided.…
Benefit-Cost Analysis | Value of Information | Health/Medicine | North America | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Outcomes | Evidence Synthesis | Mathematical Models | Cost-Effectiveness Analysis | Economics/Finance | Science/Technology | Global | Europe -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Technology Assessment | Health/Medicine | Climate/Environment | North America | Priority Setting/Ethics | Evidence Synthesis | Mathematical Models | Environmental Health | Health Systems | Policy/Regulation | Business/Industry | Economics/Finance | Energy/Engineering | Government/Law -
ArticlePublication 2023Benefits and Costs of COVID-19 Vaccine Mandates
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations …
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations for U.S. federal employees and healthcare and private sector workers. These mandates were controversial and some were halted by litigation. If they had been implemented as intended, the net benefits would depend on the course of the pandemic. If a more transmissible variant (such as Omicron) emerges, the net benefits may be large. If the pandemic instead fades, the benefits…
Benefit-Cost Analysis | Health/Medicine | North America | Mathematical Models | State-Transition | Infectious Diseases | Policy/Regulation | Business/Industry | Economics/Finance | Government/Law -
EditorialPublication 2021Scientific and Regulatory Challenges in Designing mHealth Interventions
Scientists looking for innovative ways to deliver health care have long searched for mechanisms that …
Scientists looking for innovative ways to deliver health care have long searched for mechanisms that can enable the right intervention to be delivered at the right time. Traditional delivery mechanisms have been limited both to the availability of a provider (e.g., a physician) and the location of care (e.g., a hospital or outpatient clinic). In recent years, however, numerous technological advancements—including wearable devices, mobile technologies, and the widespread development and use of user-friendly smartphone applications—have…
Technology Assessment | Health/Medicine | North America | Science/Technology -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Benefit-Cost Analysis | Health/Medicine | North America | Priority Setting/Ethics | Cost-Effectiveness Analysis | Infectious Diseases | Policy/Regulation | Economics/Finance | Global -
ArticlePublication 2021COVID and the Age–VSL Relationship
In this article, the researchers explore the approach used to value COVID-19 mortality risk reductions …
In this article, the researchers explore the approach used to value COVID-19 mortality risk reductions in analyses of lockdowns and other policies. Many rely on a population-average estimate of the value per statistical life (VSL); others adjust VSL for life expectancy at the age of death. The article explores the implications of theory and empirical studies, which suggest that the relationship between age and VSL is uncertain; these uncertainties in turn may affect whether the…
Benefit-Cost Analysis | Health/Medicine | North America | Preferences/Values | Infectious Diseases | Government/Law -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Technology Assessment | Health/Medicine | North America | Probability/Bayes | Test Performance | Infectious Diseases | Health Systems | Policy/Regulation | Government/Law | Global